Lantern Pharma raises up to $8M in registered direct offering
What's the deal? Lantern PharmaDealroom has a profile for this one. Try Dealroom → (LTRN:NASDAQ) said on Tuesday it has entered into an agreement to sell an aggregate of 3.66 million shares of its common stock at $1.09 per share in a registered direct offering. The deal, announced in September 2026, could raise up to $8 million.
Why now? The registered direct offering lets the company tap public markets quickly by selling shares directly to selected investors. It is a common route for smaller listed biotech firms to raise capital without a broader public offering.
The signal: The raise reflects continued reliance on equity markets by clinical-stage biotech companies to fund their work, even at share prices near the low single digits.
Read more: seekingalpha.com
Image credit: Generated with Gemini
